Key Highlights

  • SINTX Technologies regained Nasdaq compliance with the minimum stockholders' Equity requirement, closing a deficiency that began in May, after raising roughly $5.0 million through a private Placement and its at-the-market facility.
  • Second-quarter Revenue roughly tripled year over year to $452,000, with management guiding third-quarter revenue to double that level, driven primarily by a $3.2 million industrial ceramics order book rather than medical devices.
  • Despite the listing compliance win and revenue growth, the company's filing states substantial doubt remains about its ability to continue as a going concern, with quarterly operating cash use running near $2.6 million against $3.59 million of cash on hand.

SINTX Technologies, Inc. (NASDAQ:SINT) has spent 2026 fighting on two fronts: proving its silicon nitride ceramic can win commercial orders, and proving to Nasdaq that it belongs on the exchange. On 13 August the second fight ended in its favour.

Nasdaq's Listing Qualifications staff confirmed SINTX had regained compliance with the minimum stockholders' equity requirement, closing a deficiency that had hung over the stock since May. The confirmation rested on the Form 10-Q for the quarter ended 30 June 2026, filed two days earlier.

That filing did more than settle a listing question. It showed second-quarter revenue roughly tripling year on year and a rebuilt balance sheet, but it also repeated that substantial doubt remains about the company's ability to continue as a going concern.

What Happened

SINTX said on 13 August 2026 that Nasdaq had confirmed compliance with Listing Rule 5550(b)(1), which requires Nasdaq Capital Market companies to hold at least $2.5 million in stockholders' equity. The company reported approximately $4.83 million at 30 June. Nasdaq told it the deficiency matter is now closed.

The problem dated to late May. On 22 May SINTX disclosed it had received notice that it had fallen below the threshold, reporting stockholders' equity of about $904,000 at 31 March 2026 and meeting neither the alternative market-value nor net-income standards. A compliance plan was due by 6 July.

Chief executive Eric K. Olson said the company was pleased to have resolved the matter. Silicon nitride is a hard, non-metallic ceramic; SINTX promotes it for implants because it images clearly on X-ray, CT and MRI and, the company says, resists bacterial colonisation.

Why It Matters

For a company this small, a listing deficiency is not a paperwork issue. It narrows the financing Options a cash-consuming Business depends on, deters institutions with listing-standard mandates, and pulls management away from selling product.

It is worth being precise about how the gap closed. The rebuild came largely from financing rather than profits: in June SINTX raised roughly $5.0 million gross, comprising a $4.5 million private placement priced at $2.39 per unit and about $500,000 from its at-the-market facility. Operations helped at the margin, and the same month the company announced more than $3.2 million of contract Manufacturing purchase orders for advanced ceramic components, shipping from late 2026 into 2027.

The Numbers

Second-quarter revenue was $452,000, up from $151,000 a year earlier, almost all of it product revenue. For the six months, revenue reached $832,000 against $520,000. Cost of revenue rose far more slowly, lifting quarterly Gross Profit to $278,000 from $57,000.

Operating expenses of $3.17 million still dwarfed that, with general and administrative costs jumping to $2.32 million from $1.42 million. The operating loss was $2.89 million and the net loss $2.71 million. A $926,000 deemed Dividend tied to a Warrant modification lifted the loss attributable to common stockholders to $3.63 million, or $0.75 per share.

Cash and equivalents stood at $3.59 million at 30 June, down from $4.14 million at the end of 2025, after $5.26 million was used in operations during the half and $4.80 million raised from financing. Total Assets were $10.43 million against $5.60 million of liabilities, and shares outstanding grew to 6,613,065 from 3,970,869.

Management guided to revenue of roughly $900,000 to $1.1 million in the third quarter and $1.0 million to $1.3 million in the fourth.

What It Means for the Company

The guidance is the most informative number in the update. The low end of third-quarter guidance is about double what SINTX booked in the second quarter, and it rests mainly on the industrial ceramics order book rather than on medical devices. Contract manufacturing is the near-term revenue engine while the implant business is still being seeded.

On the medical side, the SiNAPTIC Foot and Ankle Osteotomy Wedge System received FDA 510(k) clearance in October 2025 and was implanted in a patient for the first time on 13 March 2026 at Emplify Health in La Crosse, Wisconsin. The company has since run a limited-use release and signed 12 independent orthopedic distributors.

Behind that sits a wider platform push: a completed 3D printing Facility for the SiNERGY patient-specific implant line, silicon nitride and PEEK composite work backed by a Supply agreement with Evonik, and an NIH-funded spinal fusion programme. In July SINTX hired board member Chris Lyons and his firm Southern Metrics to evaluate partnerships and licensing. The company calls OEM and private-label work an objective, but no named OEM agreement has been disclosed.

Risks Investors Should Watch

The going-concern language is the headline risk. Management concluded in the latest quarterly note that substantial doubt remains about the company's ability to continue as a Going Concern for at least twelve months, citing the half-year operating cash outflow of $5.3 million and net loss of $5.5 million.

The arithmetic is unforgiving. Operating cash use has run near $2.6 million a quarter against $3.59 million of cash at 30 June, and even at the top of fourth-quarter guidance revenue would stay below the current expense base. Further raising looks likely, which points at dilution: shares outstanding rose about 67 percent in six months, and roughly 3.77 million warrants from the June placement sit at $2.14.

The compliance win is not permanent either: $4.83 million of equity is only about $2.3 million above the Nasdaq minimum. Execution risk applies to the order book too, since SINTX noted the orders may be modified or cancelled on standard terms and the customers are not named.

What Comes Next

The immediate test is whether third-quarter shipments against the $3.2 million order book land inside the guided range, an answer due with third-quarter results in November.

Animal studies for silicon nitride sutures, meshes and wound-care products were scheduled to begin in the third quarter, with data indicated for the second half of 2026. Progress on the NIH-supported spinal implant and any output from the Southern Metrics programme are the other items to watch.

Conclusion

SINTX cleared a real hurdle in regaining Nasdaq compliance, but the way it got there, financing rather than earnings, means the underlying cash problem the deficiency reflected hasn't actually gone away. The guidance is genuinely encouraging: doubling revenue quarter over quarter based on named contract manufacturing orders is a concrete signal, distinct from the vaguer medical-device pipeline still being seeded. But even at the top of fourth-quarter guidance, revenue stays below the current expense base, and the $4.83 million equity cushion sits only about $2.3 million above the Nasdaq minimum. Whether third-quarter shipments actually land inside the guided range, not the compliance confirmation itself, is the number that will determine if this reprieve holds.